Stay updated on Pembrolizumab + Imprime PGG in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab + Imprime PGG in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab + Imprime PGG in NSCLC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:26:10.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the phase Ib dose escalation cohort of the study involving the combination of pembrolizumab and Imprime PGG for subjects with metastatic non-small cell lung cancer after progression on first-line platinum-based chemotherapy.
    Difference
    0.1%
    Check dated 2024-06-06T14:29:59.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.' This change provides a more detailed explanation of the eligibility criteria for clinical research participation.
    Difference
    52%
    Check dated 2024-05-22T21:03:55.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:52:53.000Z thumbnail image

Stay in the know with updates to Pembrolizumab + Imprime PGG in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Imprime PGG in NSCLC Clinical Trial page.